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Background:Diabetes mellitus continues to grow in global prevalence and to consume an increasing amount of health care
resources. One of the key areas of morbidity associated with diabetes is the diabetic foot. To improve the care of patients
with diabetic foot and to provide an evidence-based multidisciplinary management approach, the Society for Vascular
Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine
developed this clinical practice guideline.
Methods: The committee made specific practice recommendations using the Grades of Recommendation Assessment,
Development, and Evaluation system. This was based on five systematic reviews of the literature. Specific areas of focus
included (1) prevention of diabetic foot ulceration, (2) off-loading, (3) diagnosis of osteomyelitis, (4) wound care, and (5)
peripheral arterial disease.
Results: Although we identified only limited high-quality evidence for many of the critical questions, we used the best
available evidence and considered the patients’ values and preferences and the clinical context to develop these guidelines.
We include preventive recommendations such as those for adequate glycemic control, periodic foot inspection, and patient
and family education. We recommend using custom therapeutic footwear in high-risk diabetic patients, including those
with significant neuropathy, foot deformities, or previous amputation. In patients with plantar diabetic foot ulcer (DFU),
we recommend off-loading with a total contact cast or irremovable fixed ankle walking boot. In patients with a new DFU,
we recommend probe to bone test and plain films to be followed by magnetic resonance imaging if a soft tissue abscess or
osteomyelitis is suspected. We provide recommendations on comprehensive wound care and various débridement
methods. For DFUs that fail to improve (>50% wound area reduction) after a minimum of 4 weeks of standard wound
therapy, we recommend adjunctive wound therapy options. In patients with DFU who have peripheral arterial disease, we
recommend revascularization by either surgical bypass or endovascular therapy.
Conclusions:Whereas these guidelines have addressed five key areas in the care of DFUs, they do not cover all the aspects of
this complex condition. Going forward as future evidence accumulates, we plan to update our recommendations
accordingly. (J Vasc Surg 2016;63:3S-21S.)Diabetes is one of the leading causes of chronic disease
and limb loss worldwide, currently affecting 382 million
people. It is predicted that by 2035, the number of reported
diabetes cases will soar to 592 million.1 This disease affectsthe NYU Lutheran Medical Center, Brooklyna; the Massachusetts
eneral Hospital and Harvard Medical School, Bostonb; the Univer-
y of Michigan, Ann Arborc; the University of Washington, Seattled;
e UMass Memorial, Worcestere; the Geisinger Health System, Dan-
llef; the Brown University, Alpert Medical School, Providenceg; the
arl T. Hayden Veterans Affairs Medical Center, Phoenixh;
e University Hospitals Case Medical Center, Clevelandi; the Uni-
rsity of North Carolina School of Medicine, Chapel Hillj; the Bay-
r College of Medicine in Houston, Houstonk; and the Mayo Clinic,
ochester.l
or conflict of interest: none.the developing countries disproportionately as >80% of dia-
betes deaths occur in low- and middle-income countries.2
As the number of people with diabetes is increasing
globally, its consequences are worsening. The WorldCorrespondence: Anil Hingorani, MD, NYU Lutheran Medical Center,
150 55th St, Brooklyn, NY 11220 (e-mail: ahingorani67@gmail.com).
Independent peer review and oversight have been provided by members of the
Society for Vascular Surgery Document Oversight Committee: Peter Glo-
viczki,MD (Chair),Michael Conte,MD,Mark Eskandari,MD,Thomas For-
bes, MD, Michel Makaroun,MD, GregMoneta, MD, Russell Samson, MD,
Timur Sarac,MD,Piergiorgio Settembrini,MD, andThomasWakefield,MD.
0741-5214
Copyright  2016 by the Society for Vascular Surgery. Published by
Elsevier Inc.
http://dx.doi.org/10.1016/j.jvs.2015.10.003
3S
SUMMARY OF RECOMMENDATIONS
1. Prevention of diabetic foot ulceration
Recommendation 1: We recommend that patients with diabetes undergo annual interval foot inspections by phy-
sicians (MD, DO, DPM) or advanced practice providers with training in foot care (Grade 1C).
Recommendation 2: We recommend that foot examination include testing for peripheral neuropathy using the
Semmes-Weinstein test (Grade 1B).
Recommendation 3: We recommend education of the patients and their families about preventive foot care
(Grade 1C).
Recommendation 4:
a. We suggest against the routine use of specialized therapeutic footwear in average-risk diabetic patients (Grade
2C).
b. We recommend using custom therapeutic footwear in high-risk diabetic patients, including those with signif-
icant neuropathy, foot deformities, or previous amputation (Grade 1B).
Recommendation 5: We suggest adequate glycemic control (hemoglobin A1c < 7% with strategies to minimize
hypoglycemia) to reduce the incidence of diabetic foot ulcers (DFUs) and infections, with subsequent risk of
amputation (Grade 2B).
Recommendation 6: We recommend against prophylactic arterial revascularization to prevent DFU (Grade 1C).
2. Off-loading DFUs
Recommendation 1: In patients with plantar DFU, we recommend offloading with a total contact cast (TCC) or
irremovable fixed ankle walking boot (Grade 1B).
Recommendation 2: In patients with DFU requiring frequent dressing changes, we suggest off-loading using a
removable cast walker as an alternative to TCC and irremovable fixed ankle walking boot (Grade 2C). We sug-
gest against using postoperative shoes or standard or customary footwear for off-loading plantar DFUs (Grade
2C).
Recommendation 3: In patients with nonplantar wounds, we recommend using any modality that relieves pres-
sure at the site of the ulcer, such as a surgical sandal or heel relief shoe (Grade 1C).
Recommendation 4: In high-risk patients with healed DFU (including those with a prior history of DFU, partial
foot amputation, or Charcot foot), we recommend wearing specific therapeutic footwear with pressure-relieving
insoles to aid in prevention of new or recurrent foot ulcers (Grade 1C).
3. Diagnosis of diabetic foot osteomyelitis (DFO)
Recommendation 1: In patients with a diabetic foot infection (DFI) with an open wound, we suggest doing a
probe to bone (PTB) test to aid in diagnosis (Grade 2C).
Recommendation 2: In all patients presenting with a new DFI, we suggest that serial plain radiographs of the
affected foot be obtained to identify bone abnormalities (deformity, destruction) as well as soft tissue gas and
radiopaque foreign bodies (Grade 2C).
Recommendation 3: For those patients who require additional (ie, more sensitive or specific) imaging, particu-
larly when soft tissue abscess is suspected or the diagnosis of osteomyelitis remains uncertain, we recommend
using magnetic resonance imaging (MRI) as the study of choice. MRI is a valuable tool for diagnosis of osteo-
myelitis if the PTB test is inconclusive of if the plain film is not useful (Grade 1B).
Recommendation 4: In patients with suspected DFO for whomMRI is contraindicated or unavailable, we suggest
a leukocyte or antigranulocyte scan, preferably combined with a bone scan as the best alternative (Grade 2B).
Recommendation 5: In patients at high risk for DFO, we recommend that the diagnosis is most definitively
established by the combined findings on bone culture and histology (Grade 1C). When bone is débrided to treat
osteomyelitis, we recommend sending a sample for culture and histology (Grade 1C).
Recommendation 6: For patients not undergoing bone débridement, we suggest that clinicians consider obtain-
ing a diagnostic bone biopsy when faced with diagnostic uncertainty, inadequate culture information, or failure
of response to empirical treatment (Grade 2C).
4. Wound care for DFUs
Recommendation 1: We recommend frequent evaluation at 1- to 4-week intervals with measurements of diabetic
foot wounds to monitor reduction of wound size and healing progress (Grade 1C).
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Recommendation 1.1: We recommend evaluation for infection on initial presentation of all diabetic foot
wounds, with initial sharp débridement of all infected diabetic ulcers, and urgent surgical intervention for
foot infections involving abscess, gas, or necrotizing fasciitis (Grade 1B).
Recommendation 1.2: We suggest that treatment of DFIs should follow the most current guidelines pub-
lished by the Infectious Diseases Society of America (IDSA) (Ungraded).
Recommendation 2: We recommend use of dressing products that maintain a moist wound bed, control
exudate, and avoid maceration of surrounding intact skin for diabetic foot wounds (Grade 1B).
Recommendation 3: We recommend sharp débridement of all devitalized tissue and surrounding callus material
from diabetic foot ulcerations at 1- to 4-week intervals (Grade 1B).
Recommendation 4: Considering lack of evidence for superiority of any given débridement technique, we sug-
gest initial sharp débridement with subsequent choice of débridement method based on clinical context, avail-
ability of expertise and supplies, patient tolerance and preference, and cost-effectiveness (Grade 2C).
Recommendation 5: For DFUs that fail to demonstrate improvement (>50% wound area reduction) after a min-
imum of 4 weeks of standard wound therapy, we recommend adjunctive wound therapy options. These include
negative pressure therapy, biologics (platelet-derived growth factor [PDGF], living cellular therapy, extracellular
matrix products, amnionic membrane products), and hyperbaric oxygen therapy. Choice of adjuvant therapy is
based on clinical findings, availability of therapy, and cost-effectiveness; there is no recommendation on ordering
of therapy choice. Re-evaluation of vascular status, infection control, and off-loading is recommended to ensure
optimization before initiation of adjunctive wound therapy (Grade 1B).
Recommendation 6: We suggest the use of negative pressure wound therapy for chronic diabetic foot wounds
that do not demonstrate expected healing progression with standard or advanced wound dressings after 4 to
8 weeks of therapy (Grade 2B).
Recommendation 7: We suggest consideration of the use of PDGF (becaplermin) for the treatment of DFUs
that are recalcitrant to standard therapy (Grade 2B).
Recommendation 8: We suggest consideration of living cellular therapy using a bilayered keratinocyte/fibroblast
construct or a fibroblast-seeded matrix for treatment of DFUs when recalcitrant to standard therapy (Grade 2B).
Recommendation 9: We suggest consideration of the use of extracellular matrix products employing acellular
human dermis or porcine small intestinal submucosal tissue as an adjunctive therapy for DFUs when recalcitrant
to standard therapy (Grade 2C).
Recommendation 10: In patients with DFU who have adequate perfusion that fails to respond to 4 to 6 weeks of
conservative management, we suggest hyperbaric oxygen therapy (Grade 2B).
5. Peripheral arterial disease (PAD) and the DFU
Recommendation 1.1: We suggest that patients with diabetes have ankle-brachial index (ABI) measurements
performed when they reach 50 years of age (Grade 2C).
Recommendation 1.2: We suggest that patients with diabetes who have a prior history of DFU, prior abnormal
vascular examination, prior intervention for peripheral vascular disease, or known atherosclerotic cardiovascular
disease (eg, coronary, cerebral, or renal) have an annual vascular examination of the lower extremities and feet
including ABI and toe pressures (Grade 2C).
Recommendation 2: We recommend that patients with DFU have pedal perfusion assessed by ABI, ankle and
pedal Doppler arterial waveforms, and either toe systolic pressure or transcutaneous oxygen pressure (TcPO2)
annually (Grade 1B).
Recommendation 3: In patients with DFU who have PAD, we recommend revascularization by either surgical
bypass or endovascular therapy (Grade 1B).
Recommendation 3 (technical and implementation remarks)
d Prediction of patients most likely to require and to benefit from revascularization can be based on the Society
for Vascular Surgery (SVS) Wound, Ischemia, and foot Infection (WIfI) lower extremity threatened limb
classification.
d A combination of clinical judgment and careful interpretation of objective assessments of perfusion along with
consideration of the wound and infection extent is required to select patients appropriately for
revascularization.
d In functional patients with long-segment occlusive disease and a good autologous conduit, bypass is likely to
be preferable.
d In the setting of tissue loss and diabetes, prosthetic bypass is inferior to bypass with vein conduit.
d The choice of intervention depends on the degree of ischemia, the extent of arterial disease, the extent of the
wound, the presence or absence of infection, and the available expertise.
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enth leading cause of death in 2030.3 A further effect of the
explosive growth in diabetes worldwide is that it has
become one of the leading causes of limb loss. Every
year, >1 million people with diabetes suffer limb loss as a
result of diabetes. This means that every 20 seconds, an
amputation occurs in the world as an outcome of this debil-
itating disease.4 Diabetic foot disease is common, and its
incidence will only increase as the population ages and
the obesity epidemic continues.
Approximately 80% of diabetes-related lower extremity
amputations are preceded by a foot ulcer. The patient de-
mographics related to diabetic foot ulceration are typical
for patients with long-standing diabetes. Risk factors for ul-
ceration include neuropathy, PAD, foot deformity, limited
ankle range of motion, high plantar foot pressures, minor
trauma, previous ulceration or amputation, and visual
impairment.5 Once an ulcer has developed, infection and
PAD are the major factors contributing to subsequent
amputation.6,7
Available U.S. data suggest that the incidence of ampu-
tation in persons with diabetes has recently decreased; toe,
foot, and below-knee amputation declined from 3.2, 1.1,
and 2.1 per 1000 diabetics, respectively, in 1993 to 1.8,
0.5, and 0.9 per 1000 in 2009.8 However, including the
costs of outpatient ulcer care, the annual cost of diabetic
foot disease in the United States has been estimated to
be at least $6 billion.9 A Markov modeling approach sug-
gests that a combination of intensive glycemic control
and optimal foot care is cost-effective and may even be
cost-saving.10
DFUs and their consequences represent a major per-
sonal tragedy for the person experiencing the ulcer and
his or her family11 as well as a considerable financial
burden on the health care system and society.12 At least
one-quarter of these ulcers will not heal, and up to
28% may result in some form of amputation. Therefore,
establishing diabetic foot care guidelines is crucial to
ensure the most cost-effective health care expenditure.
These guidelines need to be goal focused and properly
implemented.13,14
This progression from foot ulcer to amputation lends
to several possible steps where intervention based on
evidence-based guidelines may prevent major amputation.
Considering the disease burden and the existing variations
in care that make decision-making very challenging for
patients and clinicians, the SVS, American Podiatric
Medical Association, and Society for Vascular Medicine
deemed the management of DFU a priority topic for clin-
ical practice guideline development. These recommenda-
tions are meant to pertain to all diabetics regardless of
etiology.
METHODS
The SVS, American Podiatric Medical Association, and
Society for Vascular Medicine selected a multidisciplinary
committee consisting of vascular surgeons, podiatrists,
and physicians with expertise in vascular and internalmedicine. A guideline methodologist, a librarian, and a
team of investigators with expertise in conducting system-
atic reviews and meta-analysis assisted the committee in the
process. The committee communicated in person and
remotely repeatedly during a period of 3 years.
Specific questions were grouped into five areas of focus
(prevention, diagnosis of osteomyelitis, wound care, off-
loading, and PAD). Each group of the committee was
assigned a focus area. The committee deemed five key ques-
tions to be in need of a full systematic review and meta-
analysis; the evidence in several other areas was summarized
by consensus of committee members. The five systematic
reviews addressed the effect of glycemic control on prevent-
ing DFU, the evidence supporting different off-loading
methods, adjunctive therapies, débridement, and tests to
predict wound healing.
The committee used the Grades of Recommendation
Assessment, Development, and Evaluation (GRADE) sys-
tem15 to rate the quality of evidence (confidence in the es-
timates) and to grade the strength of recommendations.
This system, adopted by >70 other organizations, catego-
rizes recommendations as strong Grade 1 or weak Grade 2
on the basis of the quality of evidence, the balance between
desirable effects and undesirable ones, the values and pref-
erences, and the resources and costs.
Grade 1 recommendations are meant to identify prac-
tices for which benefit clearly outweighs risk. These recom-
mendations can be made by clinicians and accepted by
patients with a high degree of confidence. Grade 2 recom-
mendations are made when the benefits and risks are more
closely matched and are more dependent on specific clinical
scenarios. In general, physician and patient preferences play
a more important role in the decision-making process in
these circumstances.
In GRADE, the level of evidence to support the
recommendation is divided into three categories: A (high
quality), B (moderate quality), and C (low quality). Con-
clusions based on high-quality evidence are unlikely to
change with further investigation, whereas those based
on moderate-quality evidence are more likely to be affected
by further scrutiny. Those based on low-quality evidence
are the least supported by current data and the most likely
to be subject to change in the future.
It is important to recognize that a Grade 1 recom-
mendation can be based on low-quality (C) evidence by
the effect on patient outcome. A full explanation of the
GRADE system has been presented to the vascular sur-
gery community.15,16 A consensus of the recommenda-
tions and level of evidence to support it was attained,
and every recommendation in this guideline represents
the unanimous opinion of the task force. Although
some recommendations are Grade 2 with Level 3 data,
the task force deemed it appropriate to present these as
the unanimous opinion of its members regarding optimal
current management. This was done with the understand-
ing that these recommendations could change in the
future but that it was unlikely that new data would
emerge soon. These guidelines are likely to be a “living
Fig. Algorithm for prevention and care of diabetic foot. ABI, Ankle-brachial index; DFU, diabetic foot ulcer; HBO,
hyperbaric oxygen; MRI, magnetic resonance imaging; NPWT, negative pressure wound therapy; PAD, peripheral
arterial disease; PTB, probe to bone; TcPO2, transcutaneous oxygen pressure; XR, radiography.
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refined, technology develops, medical therapy improves,
and new data emerge. The committee monitored the
literature for new evidence emerging after the search of
the five commissioned systematic reviews, and the group
periodically updated guidelines as new data became
available.To provide clinicians with a comprehensive guide on
the management of DFU, the committee reviewed several
relevant guidelines from other organizations and societies
(American Diabetes Association and IDSA)17,18 and adapt-
ed several evidence-based recommendations from these
guidelines. An algorithm that summarizes the prevention
and care of the DFU is depicted in the Fig.
Table. Suggested frequency for follow-up evaluation
Category Risk profile Evaluation frequency
0 Normal Annual
1 Peripheral neuropathy Semiannual
2 Neuropathy with deformity
and/or PAD
Quarterly
3 Previous ulcer or amputation Monthly or quarterly
PAD, Peripheral arterial disease.
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Recommendation 1. We recommend that patients
with diabetes undergo annual interval foot inspections by
physicians (MD, DO, DPM) or advanced practice pro-
viders with training in foot care (Grade 1C).
Evidence. The frequency of visits should be based
on the patient’s predefined risk for foot problems but
should probably be on at least a yearly basis. A history of
prior foot ulceration or amputation and a history of poor
visual acuity should be evaluated.9 The examination
should include testing for neuropathy (Semmes-Weinstein
monofilament)19 and palpation of pedal pulses; foot
deformity (hammer or claw toes, bunions, or Charcot de-
formities) should be assessed to include the presence of
pressure points and callus formation. Examination of the
toes, including between the toes for fissures and calluses
and nail problems, should be done.20 Important history
elements to elucidate include current patient foot care
practices, how often, and what is done. We recommend
basic patient education about foot care and periodic rein-
forcement, although patient compliance with therapies
rather than education has been demonstrated to have
the greatest influence on reducing foot ulceration and
amputation.21,22
During the course of evaluating patients, those deter-
mined to be at increased risk (presence of neuropathy,
ischemia, anatomic deformity) should have more frequent
foot evaluations by foot specialists and increased reinforce-
ment of direct patient education.
Whereas the ABI is the “gold standard” test for limb
blood flow, toe pressures are often better to use in diabetic
persons, given the frequency of medial arterial calcification.
Overall, ABI or toe-brachial index confers a sensitivity of
63% and a specificity of 97% in detecting hemodynamically
significant PAD. At least limited evidence suggests that
toe blood pressures may be useful in predicting not only
the potential for wound healing but also the risk of
ulceration.9
Although several risk stratification schemes have been
proposed, a simple four-level system for follow-up has
been developed by the American College of Foot and
Ankle Surgeons (Table) and appears appropriate.9
Recommendation 2. We recommend that foot exam-
ination include testing for peripheral neuropathy using the
Semmes-Weinstein test (Grade 1B).
Evidence. Peripheral neuropathy is one of the primary
causes of diabetic foot problems, with 45% to 60% of DFUs
being purely neuropathic in origin.9 In comparison to
those with intact sensation, patients with neuropathy are at
a >3.5-fold increased risk for recurrent ulceration.23 The
presence of sensory neuropathy with a foot deformity
further increases the risk of foot ulceration.
Several methods for assessing peripheral neuropathy
include the tuning fork test, a neurothesiometer, and
the Semmes-Weinstein 10-g monofilament test. The last
test is thought to be most accurate and involves a monofil-
ament sensory stimulation at defined areas on the footand over the first toe and first, third, and fifth metatarsal
areas. The examiner elicits a yes or no response from the
patient to the pressure of the filament. The recommended
frequency of this test is empirical, but yearly with the
primary care provider examination is reasonable. The evi-
dence supporting that use of this test modifies practice
is scant. However, patients with severe neuropathy as
assessed by this test have both an increased risk of
DFU and greater risk of limb loss. Patients identified as
having significant neuropathy should be considered for
increased interval examinations as well as for customized
orthotic footwear.
Recommendation 3. We recommend education of
the patients and their families about preventive foot care
(Grade 1C).
Evidence. Educating the patients and their family
about proper foot care makes empirical sense and is likely
cost-effective. This education can be provided by a physi-
cian, podiatrist, or skilled health care practitioner providing
dedicated education time to explain the basics of the care of
the foot, callus, and nail and fitting of shoes. This educa-
tion should be done during the patient’s yearly foot in-
spection examination, usually after completion of the
history and examination portion of the visit. Plain speaking
and allowing questions are important.
Studies specifically evaluating education interventions
are few and provide low-level evidence, with only modest
improvement in outcome.24,25 A very small conceptual
intensive psychosocial intervention showed reduced risk
behavior for DFU development.26 Ambulation exercise
with weight-bearing program showed benefits to those at
risk with diabetes and neuropathy, but hard outcomes of
ulcer occurrence were not reported.27
Recommendation 4.
a. We suggest against the routine use of specialized
therapeutic footwear in average-risk diabetic pa-
tients (Grade 2C).
b. We recommend using custom therapeutic footwear
in high-risk diabetic patients, including those with
significant neuropathy, foot deformities, or previous
amputation (Grade 1B).
Evidence. Diabetes is associated with a high inci-
dence of foot disorders leading to plantar pressure, and
repetitive trauma resulting from improper footwear is
a frequent contributor to DFUs.9 Approximately half of
JOURNAL OF VASCULAR SURGERY
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been attributed to improper footwear.
Proper well-fitted footwear should decrease the risk of
calluses and toe deformities. In combination with a quality
athletic walking shoe, custom foot orthoses have been
shown to decrease plantar pressures but have no significant
impact on foot pain in diabetics.28 The data regarding the
efficacy of custom diabetic footwear with respect to preven-
tion of ulceration are mixed. A small Italian trial including
69 patients reported reulceration in 28% of patients treated
with therapeutic shoes in comparison to 58% in the control
group.29 However, in a larger randomized trial including
400 patients with a healed ulcer, there was no difference
in reulceration at 2 years among those randomized to ther-
apeutic shoes with custom cork inserts (15%), therapeutic
shoes with prefabricated polyurethane inserts (14%), and
usual footwear (17%).23 Therapeutic shoes did not appear
to be protective even among those with foot insensitivity.
However, this study failed to include patients with signifi-
cant foot deformities or with a previous amputation, and
the advantages of therapeutic footwear in this population
remain unknown.
The routine prescription of therapeutic footwear
cannot be recommended over a preventive foot care pro-
gram in low-risk diabetic patients. However, patients
should be provided with sufficient information to guide se-
lection of appropriate footwear while avoiding dangerous
shoes. A study of 400 diabetic patients with a history of
healed ulceration showed that 50% of women and 27% of
men wore shoes classified as dangerous (shallow or narrow
toe box, no laces, open toes or heels, or heel height placing
undue pressure on the ball of the foot) at some point dur-
ing the day.30 Recommended footwear should include a
broad and square toe box, laces with three or four eyes
per side, padded tongue, quality lightweight materials,
and sufficient size to accommodate a cushioned insole.31
In-shoe orthotic inlays are effective in preventing ulceration
as assessed by a Cochrane review.32
Most trials have excluded high-risk diabetic patients,
including those with significant foot deformities or previ-
ous amputation or ulcers, and there may be a role for
custom shoes in these populations. In one study of 117 pa-
tients, custom footwear was successful in reducing peak
pressure points in patients at high risk of DFU, but hard
outcomes of ulceration were not reported.33 However, a
recent large randomized controlled trial (RCT) in 298
high-risk patients with custom orthoses and foot care
compared with routine care found a 48% reduction in inci-
dent ulcers at 5 years (P < .0001).34 Other guidelines sug-
gest prescription of protective footwear in diabetic patients
with arterial disease, significant neuropathy, previous ulcer
or amputation, callus formation, or foot deformity.35 We
suggest that therapeutic footwear be considered in these
high-risk populations.
Recommendation 5. We suggest adequate glycemic
control (hemoglobin A1c < 7% with strategies to minimize
hypoglycemia) to reduce the incidence of DFUs and infec-
tions, with subsequent risk of amputation (Grade 2B).Evidence. Several large trials have suggested survival
benefit and lower overall morbidity with tight glycemic
control. For example, the UK Prospective Diabetes Study
(UKPDS) showed that intensive glycemic control
decreased mortality and microvascular complications
compared with standard regimens.36 Assessment in these
studies included limb loss and revascularization. No major
differences were found with macrovascular complications,
but benefits were found for peripheral neuropathy. The
SVS commissioned comprehensive systematic review and
meta-analysis37 of nine trials enrolling 19,234 patients.
Compared with less intensive glycemic control, intensive
control (hemoglobin A1c, 6%-7.5%) was associated with a
significant decrease in risk of amputation (relative risk
[RR], 0.65; 95% confidence interval [CI], 0.45-0.94; I2 ¼
0%). Intensive control was significantly associated with
slower decline in sensory vibration threshold (mean
difference, 8.27; 95% CI, 9.75 to 6.79). There was no
effect on other neuropathic changes (RR, 0.89; 95% CI,
0.75-1.05; I2 ¼ 32%) or ischemic changes (RR, 0.92; 95%
CI, 0.67-1.26; I2 ¼ 0%).
High-risk patients may not gain as much benefit as
lower risk patients, probably because of irreversible changes
that occur late in the disease. As with many chronic dis-
eases, tight glycemic control relies much on patient compli-
ance long term to prevent DFU. Last, evidence exists that
hemoglobin A1c may be a useful marker for DFU healing;
in a study of 183 patients with DFU, every increase of 1%
in glycosylated hemoglobin decreases wound healing rate
by 0.028 cm/d.38
Recommendation 6. We recommend against prophy-
lactic arterial revascularization to prevent DFU (Grade 1C).
Evidence. No trials have been done specifically
addressing this question, but given the inherent pattern
of long-segment and distal arterial disease often present
in diabetes, risks of the invasive procedures, and induced
vascular injury by endoluminal and open revascularization,
the benefit is not apparent. Both open surgical bypass and
endovascular revascularization can have significant short-
term and long-term complications.39
Indications for arterial revascularization should be
based on the standard indications of severe claudication,
rest pain, and tissue loss.40 Primary foot ulcerations in dia-
betic neuropathy are unlikely to be directly related to
impaired large-artery blood flow; rather, they are related
to abnormal gait and foot weight distribution. As noted
in Recommendation 1, assessment to evaluate ischemia as
a factor contributing to development or nonhealing of ul-
ceration is essential. Moreover, the neuropathy of diabetes
is not primarily ischemic in nature, and there is no evidence
that revascularization reverses ischemic neuropathy except
in the setting of acute ischemia.
Conversely, for patients with diabetes and tissue loss
in the setting of significant PAD, revascularization to
prevent limb loss is well justified (Grade 1B).40 The
specific use of endovascular vs open surgical revasculari-
zation in diabetes-associated PAD is beyond the scope of
this review.
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Recommendation 1. In patients with plantar DFU,
we recommend off-loading with a total contact cast
(TCC) or irremovable fixed ankle walking boot (Grade 1B).
Recommendation 2. In patients with DFU requiring
frequent dressing changes, we suggest off-loading using a
removable cast walker (RCW) as an alternative to TCC and
irremovable fixed anklewalking boot (Grade2C).We suggest
against using postoperative shoes or standard or customary
footwear for off-loading plantar DFUs (Grade 2C).
Recommendation 3. In patients with nonplantar
wounds, we recommend using any modality that relieves
pressure at the site of the ulcer, such as a surgical sandal
or heel relief shoe (Grade 1C).
Recommendation 4. In high-risk patients with healed
DFU (including those with a prior history of DFU, partial
foot amputation, or Charcot foot), we recommend wear-
ing specific therapeutic footwear with pressure-relieving
insoles to aid in prevention of new or recurrent foot ul-
cers (Grade 1C).
Evidence. Off-loading diabetic foot wounds is a key
component of care and is an essential management strat-
egy.9,41-44 Because most plantar ulcers result from repeti-
tive or high plantar pressures, it therefore follows that such
pressures must be ameliorated or reduced to allow healing
to occur.45 Similarly, many lesions occurring on nonplantar
surfaces can be attributed to pressure from tight footwear or
constricting bandages. Accordingly, these offending pres-
sures must also be eliminated to ensure healing. Although
not the sole component of care for DFUs, pressure
reduction (off-loading) must occur in conjunction with any
other basic or advanced wound therapy.9,35,44,46-48 Once
healed, prevention of recurrent or new ulcers must be a
priority for ongoing care of high-risk feet, including those
with previous partial foot amputation. Numerous guidelines
and publications therefore recommend the provision of
protective footwear with pressure-relieving insoles as a
primary prevention strategy in this regard.9,33,41,42,49-54
Unfortunately, there is often a lack of adherence to off-
loading strategies on the part of affected patients as well
as a disconnect between guideline recommendations and
clinical practice.41,42,51,55,56
Numerous off-loading modalities have been reported
for DFUs, including TCCs, braces, RCWs, irremovable
cast walkers (often referred to as instant TCCs [iTCCs]),
half-shoes, modified surgical shoes, foot casts, and various
felt or foam dressings.42,43,51,57-69 Whereas each device
has its advantages for any given patient, almost any off-
loading modality is superior to no off-loading for the man-
agement of DFUs.43 For many years, the TCC has been
considered the most effective off-loading modality for
DFUs by virtue of its pressure redistribution properties as
well as irremovability.42,70,71 An early small trial by Mueller
et al63 in 1989 showed superiority of TCC over standard
wound care and accommodative footwear in healing of
DFUs. Significantly, 90% of TCC-treated ulcers healed in
a mean time of 42 days compared with 32% of thetraditional dressing group that healed in a mean of
65 days (P < .05). Several other prospective studies have
also confirmed the clinical efficacy of the TCC in healing
of DFUs.58,66,71-74 Although not as effective in healing
of ulcers, removable devices such as cast walkers and half-
shoes have also become popular for off-loading
DFUs.58,75 Patient adherence to the continual use of the
devices is less than optimal, making their removability a
likely detriment to ulcer healing.76 Recognizing this, Arm-
strong et al57 performed a 12-week randomized trial
comparing ulcerated patients treated with an irremovable
cast walker (iTCC) with a group randomized to an
RCW. As hypothesized, a significantly higher proportion
of patients healed in the iTCC group than in the RCW
group (82.6% [19 patients] vs 51.9% [14 patients]; P ¼
.02; odds ratio, 1.8; 95% CI, 1.1-2.9). With confirmation
that the irremovable device performed significantly better
than that which was removable, the next obvious question
was whether the iTCC could perform as well as the TCC in
healing DFUs during a similar 12-week time frame. In the
same month, Katz et al64 published the results of their
RCT comparing these two irremovable devices. In an
intention-to treat analysis, the proportions of patients
with ulcers that healed in 12 weeks in the TCC and
iTCC groups were 74% and 80%, respectively (P ¼ .65).
Healing times were also nonsignificantly different, with
median healing times of 5 weeks and 4 weeks in the
TCC and RCW groups, respectively. This was followed
by several other studies using different but similar irremov-
able RCWs, each showing nonsignificant differences in
rates of healing and healing times.62,68,71 Subsequently,
most recent DFU clinical trials and guidelines have recom-
mended that irremovable devices be used as preferred off-
loading modalities for plantar DFUs.9,35,44,53,77
Once healed, these patients must be prescribed thera-
peutic footwear with pressure-relieving insoles to prevent
recurrent or new foot lesions.9,41,42,52,78 In-shoe plantar
pressure analysis can be useful in identifying high-
pressure locations for customization of insoles and foot-
wear.33,49 Several prospective studies have demonstrated
that patients wearing prescriptive pressure-relieving foot-
wear have significantly fewer recurrences of ulceration
compared with those persons not wearing therapeutic
shoes.29,79 The same is true for all high-risk patients,
including those with a prior history of DFU, partial foot
amputations, or Charcot foot.9 Such patients have higher
than normal plantar pressures because of underlying struc-
tural deformities or biomechanical perturbations (often
secondary to peripheral neuropathy).80-82 Whereas surgical
off-loading can be beneficial in properly selected patients,83
these deformities and high plantar pressures need to be
ameliorated with appropriate footwear.9,41,51 Unfortu-
nately, patient adherence to wearing of prescription foot-
wear is often insufficient and requires further attention to
reduce the risk for reulceration.41,56
The SVS commissioned a systematic review84 to eval-
uate the different off-loading methods. Their findings
and those of a Cochrane systematic review43 were
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evidence is somewhat low and the available trials are small
with several limitations. The review summarized 19 inter-
ventional studies, of which 13 were RCTs, including data
from 1605 patients with DFUs using an off-loading
method. The quality of the included studies ranges from
low to moderate. This analysis demonstrated improved
wound healing with total contact casting over RCW, ther-
apeutic shoes, and conventional therapy. There was no
advantage of irremovable cast walkers over total contact
casting. There was improved healing with half-shoe
compared with conventional wound care. Therapeutic
shoes and insoles reduced relapse rate in comparison with
regular footwear. Data were sparse regarding other off-
loading methods.
3. Diagnosis of diabetic foot osteomyelitis (DFO)
The diagnosis of DFO relies heavily on the correlation
between the clinical, histologic, and imaging studies pre-
sented in the individual patient. Foot infection is the
most frequent diabetic complication requiring hospitaliza-
tion and the most common precipitating event leading to
lower extremity amputation.85,86 The mal perforans ulcer
plays a pivotal role as the major predisposing factor to
infection in the diabetic foot. This type of ulceration is
commonly a result of persistent trauma and repeated
plantar pressure on the insensate foot. The breakdown
of the skin leads to the increased probability of wound
infection that can subsequently lead to deep tissue infec-
tion and inevitably include bone infiltration that results
in the presence of contiguous osteomyelitis. The key un-
derlying risk factors that contribute to the development
of DFIs are neuropathy, vasculopathy, and, to a lesser
extent, immunopathy.86 Diagnosis and treatment of oste-
omyelitis are viewed as the most challenging and contro-
versial aspects of managing this infectious process.87
DFO may be present in up to 20% of mild to moderate
infections and in 50% to 60% of severely infected
wounds.88 One of the most difficult aspects of diagnosing
DFO is differentiating it from Charcot neuroarthropathy,
which is noninfectious and may often coexist in the pres-
ence of a DFU and an insensate foot. Although the path-
ophysiologic mechanism of osteomyelitis seen in the
diabetic patient in the presence of an ulcer is better and
more clearly understood than in previous years, the sys-
tematic treatment regimen is still not well defined. The
literature supports the role of an interdisciplinary team
as well as a multimodality approach to the DFI to improve
outcomes and to decrease amputation rates.86 In the arena
of classification of a wound infection and the severity
and outcome of treatment of a DFI, there is no empirical
evidence that one classification system (Meggit-Wagner,
PEDIS [perfusion, extent/size, depth/tissue loss, infec-
tion, and sensation], SAD/SAD [size (area, depth), sepsis,
arteriopathy, and denervation], SINBAD [site, ischemia,
neuropathy, bacterial infection, area, and depth], or UT
[University of Texas]) or one wound score (USI, DUSS
[Diabetic Ulcer Severity Score], MAID [palpable pedalpulses (I), wound area (A), ulcer duration (D), and pres-
ence of multiple ulcerations (M)], or DFI Wound Score)
is better than any other.89 The multimodal approach
involving clinical evaluation, laboratory testing, and a
stepwise approach to imaging modalities is the best way
to confirm and to determine the best treatment regimen
for the patient with DFO.
The following section presents recommendations and
evidence consistent with the most current IDSA guidelines
on the diabetic foot.18
Recommendation 1. In patients with a DFI with an
open wound, we suggest doing a probe to bone (PTB)
test to aid in diagnosis (Grade 2C).
Evidence. PTB has fair sensitivity and specificity for
diagnosis of osteomyelitis (60% and 91%, respectively)90
and high positive predictive value (89%)91 in patients
with high pretest probability of disease. The accuracy in
patients at lower pretest probability is lower.87 PTB has
only fair reproducibility among examiners.92 PTB is inex-
pensive and poses minimal risk to the patient. Therefore, it
is helpful in ruling in osteomyelitis, but when the result
is negative, additional testing is needed to rule out the
condition. The quality of this evidence is low as it mainly
consists of small observational studies that did not measure
the impact of test results on patient outcomes but rather
provided diagnostic accuracy measures.
Recommendation 2. In all patients presenting with a
new DFI, we suggest that serial plain radiographs of the
affected foot be obtained to look for bone abnormalities
(deformity, destruction) as well as soft tissue gas and radi-
opaque foreign bodies (Grade 2C).
Evidence. Plain radiographs of the foot have relatively
low sensitivity and specificity for confirming or excluding
osteomyelitis with a fair sensitivity and specificity (54%
and 68%, respectively) and low diagnostic odds ratio of
2.84, suggesting low to moderate accuracy.90,92 Radio-
graphic findings are only marginally predictive of osteo-
myelitis if positive and even less predictive of the absence of
osteomyelitis if negative.93
The quality of this evidence is low as there are no
specific studies identified that included obtaining and
monitoring of sequential plain radiographs over time.
Clinicians might consider using serial plain radiographs to
diagnose or to monitor suspected DFO, with evidence
that changes in radiologic appearance during an interval
of at least 2 weeks are more likely to predict the presence
of osteomyelitis than a single radiographic study.18
Recommendation 3. For those patients who require
additional (ie,more sensitive or specific) imaging, particularly
when soft tissue abscess is suspected or the diagnosis of
osteomyelitis remains uncertain, we recommend using MRI
as the study of choice. MRI is a valuable tool for diagnosis
of osteomyelitis if the plain film is not useful (Grade 1B).
Evidence. The pooled sensitivity and specificity of
MRI for DFO were excellent (90% and 79%, respectively),
with the diagnostic odds ratio of 24.4 indicating excellent
discriminant power.90 More recently performed studies
reported lower diagnostic odds ratios compared with the
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recent study designs were perhaps better.94
The quality of evidence supporting the use of MRI
in DFO is moderate to high. The meta-analysis included
four large prospective studies, with two of the four
using consecutive recruitment, although only one was
recent.90,94 MRI is generally considered the best of the
currently available advanced imaging technique options
for diagnosis of osteomyelitis. Limitations of using
MRI include the limited availability of radiologists with
expertise in musculoskeletal images, limited availability,
and high cost. Differentiating osteomyelitis from Charcot
neuroarthropathy remains challenging. The risk of MRI
to patients is minimal.18
Recommendation 4. In patients with suspected DFO
for whom MRI is contraindicated or unavailable, we sug-
gest a leukocyte or antigranulocyte scan, preferably com-
bined with a bone scan as the best alternative (Grade 2B).
Evidence. Nuclear medicine scans have a high sensi-
tivity but a relatively low specificity (especially bone scans).
The pooled sensitivity and specificity were 81% and 28%,
respectively, with the pooled diagnostic odds ratio of
2.10, which indicated poor discriminating ability. The
accuracy for detection of osteomyelitis using nuclear med-
icine bone scan and indium-labeled leukocyte scans is in
general low to moderate.90 Although the combination of
bone scanning and labeled leukocyte scan provides the best
scanning accuracy outside of MRI, it remains labor-
intensive and costly, and it is still not as specific as MRI.
Recommendation 5. In patients at high risk for DFO,
we recommend that the diagnosis is most definitively estab-
lished by the combined findings on bone culture and his-
tology (Grade 1C). When bone is débrided to treat
osteomyelitis, we recommend sending a sample for culture
and histology (Grade 1C).
Evidence. The literature provides only a limited num-
ber of studies that examined clinical examination tech-
niques for diagnosis of DFO, making it difficult to
produce robust estimates. More studies are needed to
give enough data for predictive values.
Recommendation 6. For patients not undergoing
bone débridement, we suggest that clinicians consider
obtaining a diagnostic bone biopsy when faced with diag-
nostic uncertainty, inadequate culture information, or fail-
ure of response to empirical treatment (Grade 2C).
Evidence. Cultures of bone specimens provide more
accurate microbiologic data than soft tissue for deter-
mining the presence of DFO and have been shown to pro-
vide greater accuracy as to the specific organisms causing
the infection; therefore, the treatment can be more tailored
for better treatment outcome. A retrospective multicenter
study demonstrated that patients who underwent bone
culture-guided antibiotic treatment had a significantly
better outcome.90
4. Wound care for DFUs
Attentive care to the diabetic foot wound requires
frequent inspection with irrigation and débridement,protective dressings, infection and inflammation control,
and plantar off-loading.9,18,35,48,95 These components are
essential to preserve a moist, noninfected wound environ-
ment that will progress through granulation and epithelial-
ization to full healing in a timely manner.
Evaluation and initial treatment of diabetic foot
wounds. Recommendation 1. We recommend frequent
evaluation at 1- to 4-week intervals with measurements
of diabetic foot wounds to monitor reduction of wound
size and healing progress (Grade 1C).
Evidence. Percentage reduction in wound size is an
early predictor of treatment outcome.35,96-99 Wound area
reduction of 10% to 15% per week or $50% area reduction
in 4 weeks results in increased likelihood of healing with
decreased complications of infection and amputation.
Although there are no studies that evaluated the benefits
and utility of different wound check intervals, studies
that monitored healing progression of DFUs strongly
correlated 50% healing at 4 weeks with final full healing by
16 weeks. By measuring wounds at 1- to 4-week intervals,
the clinician documents healing progress and identifies the
basis for treatment modification.
Recommendation 1.1
We recommend evaluation for infection on initial pre-
sentation of all diabetic foot wounds, with initial sharp
débridement of all infected diabetic ulcers, and urgent sur-
gical intervention for foot infections involving abscess, gas,
or necrotizing fasciitis (Grade 1B).
Recommendation 1.2
We suggest that treatment of DFIs should follow
the most current guidelines published by the IDSA
(Ungraded).
Evidence. Diagnosis and management of DFIs have
been systematically addressed with IDSA evidence-based
clinical practice guidelines.18 On careful review of the
most current IDSA clinical practice guideline, this com-
mittee notes that the scope and depth of these recom-
mendations represent the most current standard of care for
management of DFIs.
Wound dressings. Recommendation 2. We recom-
mend use of dressing products that maintain a moist
wound bed, control exudate, and avoid maceration of sur-
rounding intact skin for diabetic foot wounds (Grade 1B).
Evidence. Dressings are used to provide a favorable
wound environment for healing. A moist wound bed for
open wounds is the well-documented standard of care and
supported by evidence-based guidelines.35,48,95,100 Optimal
wound care provides moist coverage, absorption of exudate,
autolytic débridement, prevention of infection, and pro-
motion of granulation. Nonadherent dressings that protect
the wound bed are standard treatment for most wounds.
There is little quality evidence to support the use of any
single dressing product over another in promoting a moist
wound bed for the DFU.35,48,95,101-103 Cochrane reviews
of RCTs with meta-analysis for hydrogels,104 hydrocol-
loids,105 foam dressings,106 and alginates107 found insuffi-
cient evidence to support any one of these dressing groups
over another for acceleration of wound healing. There is
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popular wound dressings, including honey108-110 and topical
silver.111-114 There is limited evidence that hyaluronic acid-
containing products are associated with positive effects
on wound healing compared with standard products.115
Numerous trials of variable quality targeting therapy for
DFUs have been challenged by inadequate sample size,
difficulty in follow-up, nonrandomization of treatment
arms, nonblinded outcome assessment, and concurrent
multiple interventions.116 Heterogeneity of the population
and multiple variables regarding both the person and the
wound limit trial design and implementation.
As individual wounds differ in their properties, dressing
selection should be based on the characteristics of the
wound, cost, and ease of use. Dry wounds benefit from
hydrogels and hydrocolloids to preserve moisture. Foam
dressings and alginates absorb drainage and are preferred
for exudative wounds. Consideration should be made to
change a product if wound area reduction fails to meet rec-
ommended guidelines (Recommendation 1). Adverse ef-
fects such as maceration, infection, or further loss of
tissue should prompt a change in wound dressing modality.
With respect to cost, standard dressings that have longer
wearing times, do not require trained personnel for applica-
tion, maintain adherence to the skin but nonadherence to
the wound bed, and are comfortable may result in less
overall expenditure for product purchase.
Débridement of diabetic foot wounds. Recommen-
dation 3. We recommend sharp débridement of all devital-
ized tissue and surrounding callus material from diabetic
foot ulcerations at 1- to 4-week intervals (Grade 1B).
Evidence. Standard or “good” wound care for DFUs
has long been defined to include daily dressing changes,
sharp débridement of ulcer, systemic control of any present
infection, and off-loading of pressure.35,48,95,100,117
Débridement of DFUs allows drainage of exudate and
removal of nonviable tissue, thus reducing infection by
decreasing bacterial burden. It permits valid assessment of
the wound size, depth, and characteristics and encourages
healing. Removal of surrounding callus material reduces
pressure load on the wound.118 Débridement intervals are
patient customized, dependent on production rate of ex-
udates and presence of devitalized tissue.
Recommendation 4. Considering lack of evidence for
superiority of any given débridement technique, we sug-
gest initial sharp débridement with subsequent choice of
débridement method based on clinical context, availability
of expertise and supplies, patient tolerance and preference,
and cost-effectiveness (Grade 2C).
Evidence. Débridement methods include surgical
(sharp or standard), larval therapy, hydrotherapy, ultra-
sound, hydrogel, various occlusive dressings, and enzy-
matic.117 Wet-to-dry dressings, in which saline-soaked
gauze is allowed to dry on the wound then physically rip-
ped off, were a past standard mechanical débridement
technique. These have fallen out of favor as the débride-
ment is nonselective, harming viable tissue in addition to
removal of necrotic debris, and may be painful.119In examining controlled studies on various methods of
débridement, the quality of evidence remains fair to moder-
ate. The SVS commissioned systemic review120 of 13 inter-
ventional studies (10 RCTs and three nonrandomized
studies), including data from 788 patients. The risk of bias
in the included studies was moderate. Meta-analysis of three
RCTs showed that autolytic débridement significantly
increased healing rate compared with standard wound
débridement (RR, 1.89; 95% CI, 1.35-2.64). Meta-
analysis of four comparative studies (one RCT) showed
that larval débridement reduced amputation (RR, 0.43;
95% CI, 0.21-0.88) but not complete healing (RR, 1.27;
95% CI, 0.84-1.91). No significant difference in wound
healing was found between autolytic débridement and larval
débridement (one RCT). Surgical débridement had shorter
healing time compared with conventional wound care (one
RCT). Ultrasound débridement was associated with reduc-
tion in wound size compared with surgical débridement.
Hydrosurgical débridement had similar wound healing out-
comes to standard surgical débridement.
In general, comparative effectiveness evidence was of
low quality, and the débridement method is recommended
to be at the clinician’s discretion, with the goal of wound
size reduction to full healing. The chosen débridement
method should encourage patient compliance with the
overall care plan.
Indications for adjunctive therapies. Recommenda-
tion 5. For DFUs that fail to demonstrate improvement
(>50% wound area reduction) after a minimum of 4 weeks
of standard wound therapy, we recommend adjunctive
wound therapy options. These include negative pressure
therapy, biologics (PDGF, living cellular therapy, extracel-
lular matrix products, amnionic membrane products), and
hyperbaric oxygen therapy. Choice of adjuvant therapy
is based on clinical findings, availability of therapy, and
cost-effectiveness; there is no recommendation on
ordering of therapy choice. Re-evaluation of vascular sta-
tus, infection control, and off-loading is recommended to
ensure optimization before initiation of adjunctive wound
therapy (Grade 1B).
Evidence. Adjunctive therapies for the healing of
DFUs should be considered after all standard of care mea-
sures have been implemented.44,96-99,121 Standard,
comprehensive care should include wound off-loading,
local wound débridement, control of edema, control of
bioburden, and wound moisture balance with appropriate
dressings. Standard of care for diabetic foot ulcerations will
lead to improvement in the majority of cases, and only in
those cases without improvement should adjunctive mo-
dalities be used. The cost of these therapies can be high,
and the evidence supporting their use is not sufficiently
strong to justify their use as primary therapy without an
attempt at lower cost, evidence-based methods. Failure to
demonstrate improvement after 4 weeks of treatment
should lead the clinician to reassess the adequacy of and
compliance with débridement/wound care, proper off-
loading of the DFU, and adequacy of the arterial perfu-
sion of the foot before considering adjunctive treatment
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be performed before the use of adjuvant therapies to
ensure that offloading is implemented, bioburden is well
controlled, vascular supply is optimized, and exudate is not
excessive.
The SVS commissioned a systematic review121 to eval-
uate the efficacy of three adjunctive therapies: hyperbaric
oxygen therapy, arterial pump devices, and pharmacologic
agents (pentoxifylline, cilostazol, and iloprost). They iden-
tified 18 interventional studies, of which nine were ran-
domized, enrolling 1526 patients. The quality of the
included studies ranged from low to moderate. Arterial
pump devices had a favorable effect on complete healing
in one small trial compared with hyperbaric oxygen therapy
and in another small trial compared with placebo devices.
Neither iloprost nor pentoxifylline had a significant effect
on amputation rate compared with conventional therapy.
No comparative studies were identified for cilostazol in
DFUs. Evidence was most supportive for hyperbaric oxy-
gen therapy.
Recommendation 6. We suggest the use of negative
pressure wound therapy (NPWT) for chronic diabetic
foot wounds that do not demonstrate expected healing
progression with standard or advanced wound dressings af-
ter 4 to 8 weeks of therapy (Grade 2B).
Evidence. NPWT is safe and effective treatment for
DFUs. A multicenter RCT (n ¼ 342) demonstrated
NPWT to be as safe as and more efficacious than advanced
moist wound therapy (AMWT) for DFUs.122 Patients
treated with NPWT healed to closure faster, experienced
significantly fewer secondary amputations, and required
significantly fewer home care therapy days than patients
treated with AMWT.
Other RCTs and studies demonstrated reduced time
to complete healing of DFUs, reduced duration and fre-
quency of hospital admission, and decreased rate of
amputation compared with AMWT/débridement123;
decreased healing time and improved quality of life124;
increased rate of appearance of granulation tissue125;
reduced length of hospitalization and reduced amputa-
tion rates with functional residual extremity126; reduced
time to granulation, clearing of bacterial infection, and
successful granulation127; and significant reduction in
wound size compared with conventional therapy.127 Sys-
tematic reviews35,48,102,128-131 summarized recommen-
dations with moderate to strong evidence for use of
NPWT in DFUs. Retrospective analysis of reimburse-
ment claims demonstrated reduced numbers of am-
putations in NPWT groups vs traditional therapies,
regardless of depth of wound,132 and more rapid success-
ful wound treatment end point and decreased resource
utilization due to reduction in nursing visits.133 Consid-
eration of high cost of NPWT products and access to
trained personnel for application of NPWT dressings
should be weighed in choosing this treatment modality.
Recommendation 7. We suggest consideration of the
use of PDGF (becaplermin) for the treatment of DFUs
that are recalcitrant to standard therapy (Grade 2B).Evidence. Although multiple growth factors have been
studied in clinical trials, to date, only PDGF has been
approved by the Food and Drug Administration for the
treatment of DFUs.134-136 Becaplermin (Regranex) is a
recombinant human BB isoform of PDGF suspended in a
gel designed for topical application. PDGF has a central
role in the stimulation of tissue regeneration by promoting
angiogenesis through macrophage secretion of vascular
endothelial growth factor (VEGF), fibroblast activity, and
epithelial migration. Becaplermin is applied daily to the
DFU and covered with saline-moistened gauze. It has been
studied clinically in four prospective, randomized, placebo-
controlled trials. In a meta-analysis of these studies, Smiell
et al137 aggregated the 922 patients studied for analysis.
Four groups were identified: patients treated with a stan-
dard regimen of good ulcer care and wet-to-dry gauze
dressings, those treated with good ulcer care plus placebo
gel, and those treated with good ulcer care plus beca-
plermin gel at two different doses. Fifty percent of ulcers
treated with the higher dose of becaplermin for 20 weeks
healed, compared with 36% treated with placebo gel (P ¼
.007). Adverse events were rare, and the only medication-
related event was local tissue sensitivity in 2%.
Multiple cost-efficacy analyses have been performed on
the use of becaplermin to treat DFUs. Kantor and Margo-
lis138 studied 26,599 patients from a clinical wound treat-
ment database and reported effective wound closure at
20 weeks in 31% of those treated with standard care
compared with 43% treated with becaplermin. The incre-
mental cost of increasing the odds of healing by 1% over
standard therapy was $36.59 for becaplermin. Studies
from Canada and Sweden also found becaplermin to be
cost-effective therapy for the treatment of DFUs. In
2008, the Food and Drug Administration released a black
box warning concerning the risk of fatal cancers in patients
treated with becaplermin. Based on long-term follow-up
studies of patients enrolled in randomized studies, there
was no increased risk of malignancy in patients treated
with becaplermin, but those who developed malignant
neoplasms had a greater risk of dying of them.139 This in-
formation is based on a small number of observations, so it
should be interpreted with caution. It does emphasize,
however, that the drug should be considered only in refrac-
tory DFUs failing to respond to standard therapy.
Recommendation 8. We suggest consideration of
living cellular therapy using a bilayered keratinocyte/fibro-
blast construct or a fibroblast-seeded matrix for treatment
of DFUs when recalcitrant to standard therapy (Grade 2B).
Evidence. Apligraf (Organogenesis, Canton, Mass) is a
cultured bilayer skin substitute originating from neonatal
foreskin.140 A bovine collagen lattice is used as a base to
support the organization of dermal fibroblasts and epithe-
lial cells seeded after expansion of the separated neonatal
cells. A layer of allogeneic keratinocytes is cultured over the
fibroblast layer to form a stratified epidermis. The bilayer
has a structure similar to human skin, with the absence of
hair follicles or sweat glands. The growth factors and cy-
tokines secreted by the cellular components of Apligraf
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forming growth factor b, and multiple interleukins, paral-
leling those secreted by healthy human skin. The product
requires a well-granulated wound bed in which exudate
and bacterial levels have been controlled to yield positive
results.
Apligraf was studied in a prospective randomized
multicenter trial for the treatment of DFUs.141 At 24 cen-
ters, 208 patients were treated with standard DFU care
(débridement, foot off-loading) and saline-moistened
gauze or standard DFU care and Apligraf application. After
12 weeks of treatment, 56% of Apligraf-treated wounds
were closed, compared with 38% in the control group.
The odds ratio for complete healing was 2.14 (95% CI,
1.23-3.74). The incidence of osteomyelitis was significantly
less frequent in Apligraf-treated patients (2.7%) than in
controls (10.4%; P ¼ .04). Ipsilateral toe or foot amputa-
tion was also significantly less frequent in the Apligraf
group (6.3%) than in the control group (15.6%). Cost-
effectiveness analysis revealed 12% reduction in costs dur-
ing the first year of treatment compared with standard
wound care alone.142 The increased ulcer-free time
coupled with a reduced risk of amputation to a large extent
offset the initial costs of the product.
Dermagraft. Dermagraft (Organogenesis) is an allo-
geneic dermal fibroblast culture derived from human
neonatal foreskin samples and grown on a biodegradable
scaffold.143 The resulting three-dimensional matrix can
be implanted into chronic nonhealing wounds to supply
functional fibroblasts and their corresponding expressed
proteins. The scaffold biodegrades during a 1- to 2-week
period, leaving behind only cellular components and pro-
teins. Several in vitro studies have evaluated the ability of
Dermagraft to express clinically significant quantities of
growth factors after cryopreservation and thawing. VEGF,
PDGF-A, and insulin-like growth factor I were all found to
recover to significant levels as measured by enzyme-linked
immunosorbent assay in wounds to which Dermagraft was
applied.
The pivotal study of Dermagraft in DFUs was a single-
blinded, randomized, controlled investigation at 35 centers
enrolling 314 patients comparing standard DFU care with
standard care plus the weekly application of Dermagraft for
up to 8 weeks.144 Clinical studies evaluating Dermagraft
and Apligraf were not double blinded because the unique
characteristics of the devices preclude the use of a placebo
that cannot be distinguished from the true product. Stan-
dard care in both groups consisted of routine sharp
débridement, pressure off-loading, and saline-moistened
gauze dressings. Of the 314 patients enrolled, 245 evalu-
able patients completed the study. Results showed that
treatment with Dermagraft produced a significantly greater
proportion (30%) of healed ulcers compared with the con-
trol group (18%). The number of ulcer-related adverse
events (local wound infection, osteomyelitis, cellulitis)
was significantly lower in the Dermagraft-treated patients
(19%) than in the control patients (32%; P ¼ .007). Similar
findings were noted in a smaller clinical trial (n ¼ 28) withmore ulcers closed, faster closure, higher percentage of ul-
cers closed by week 12, and fewer infections than in the
control patients.145
Recommendation 9. We suggest consideration of the
use of extracellular matrix products employing acellular hu-
man dermis or porcine small intestinal submucosal tissue as
an adjunctive therapy for DFUs when recalcitrant to stan-
dard therapy (Grade 2C).
Evidence. A variety of tissue constructs have recently
become available, approved through the 510K mechanism
as adjunctive therapies for the healing of chronic wounds
including DFUs. This includes products incorporating hu-
man tissue (acellular dermis, amniotic membrane, cryopre-
served skin, others) or animal tissue (bladder tissue,
pericardial tissue, intestinal submocosa). Of the multitude
of these products, only two have been found to provide
benefit compared with standard DFU treatment. A porcine
small intestinal submucosa (SIS) construct (OASIS; Cook
Biotech, West Lafayette, Ind) has been tested in a prospec-
tive randomized trial. In this study, 73 patients with DFUs
were randomized to treatment with standard care and SIS
compared with standard care and becaplermin. More
wounds in the SIS-treated group healed at 12 weeks (49%
vs 28% treated with becaplermin; P ¼ .055). Although it is
not statistically superior to treatment with PDGF, it seems
reasonable to consider the use of SIS, given the previous
trials demonstrating improved healing rates with beca-
plermin compared with standard DFU therapy.
An acellular human dermal matrix (Graftjacket; Wright
Medical Technology, Memphis, Tenn) was studied in a
prospective randomized multicenter trial in 87 patients
with DFUs compared with standard care. Significantly
more wounds treated with the human dermal matrix
healed at 12 weeks (69.6%) than with control (46.2%;
P ¼ .03).146,147
It must be stressed that these adjunctive therapies
are not a substitute for the standard principles of wound
healing. If the wound is not well prepared before applica-
tion of a growth factor or living tissue substitute, there is
little potential for wound stimulation or accelerated heal-
ing. Strict wound off-loading is required for maximum
benefit.
Recommendation 10. In patients with DFU that fails
to respond to 4 to 6 weeks of conservative management,
we suggest hyperbaric oxygen therapy (Grade 2B).
Evidence. The SVS-commissioned systematic re-
view121 demonstrated that hyperbaric oxygen therapy im-
proves wound healing and reduces the risk of amputation.
In multiple randomized trials, hyperbaric oxygen therapy
was associated with increased healing rate (Peto odds ratio,
14.25; 95% CI, 7.08-28.68) and reduced amputation rate
(Peto odds ratio, 0.30; 95% CI, 0.10-0.89) compared with
conventional therapy. Several other systematic reviews
showed similar results. Considering the cost and the
burden of prolonged daily treatment, patients should be
selected for this therapy carefully. Using transcutaneous
oximetry values can help stratify patients and predict those
who are most likely to benefit.148
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Recommendation 1.1. We suggest that patients with
diabetes have ABI measurements performed when they
reach 50 years of age (Grade 2C).
Recommendation 1.2. We suggest that patients with
diabetes who have a prior history of DFU, prior abnormal
vascular examination, prior intervention for peripheral
vascular disease, or known atherosclerotic cardiovascular
disease (eg, coronary, cerebral, or renal) have an annual
examination of the lower extremities and feet including
ABI and toe pressures (Grade 2C).
Recommendation 2. We recommend that patients
with DFU have pedal perfusion assessed by ABI, ankle
and pedal Doppler arterial waveforms, and either toe sys-
tolic pressure or transcutaneous oxygen pressure (TcPO2)
annually (Grade 1B).
Evidence. DFUs are a common, costly, and complex
complication of diabetes. One in four patients with dia-
betes will develop a foot ulcer during his or her lifetime.149
DFUs are important because of their negative impact on
quality of life, contribution to increased mortality, and
strong link with major limb amputation.150 Up to 85% of
major limb amputations in patients with diabetes are pre-
ceded by foot ulcers.5
DFUs are multifactorial and are generally categorized
as neuropathic, neuroischemic, and ischemic. There are
strong data to suggest that the pathophysiologic mecha-
nism of DFUs has changed during the last 20 years, with
an increasing proportion of ischemic and neuroischemic ul-
cers. It is currently estimated that at least 65% of DFUs
have an ischemic component, nearly double that reported
in the early 1990s.150,151 This change has important impli-
cations in provision of care and outcomes analysis because
patients with ischemic ulcers suffer from a higher recur-
rence rate, double the amputation rate, and inferior main-
tenance of independence and ability to ambulate compared
with patients with neuropathic ulcers.152
The relationship of diabetes and PAD is complex. Dia-
betes is a major risk factor for PAD, and depending on its
definition, PAD prevalence rates are 10% to 40% among
the general population of patients with diabetes.151 The
combination of diabetes and PAD is a sinister one, with
an associated 5-year mortality rate approaching 50%, higher
than for many forms of cancer.150 The mortality of a pa-
tient with PAD and diabetes who suffers an amputation
is 50% at 2 years.
Clearly, identification and comprehensive medical
management of PAD in patients with diabetes are impor-
tant. In addition, in patients with DFUs, PAD should be
identified and graded,153 and if it is contributing to delayed
healing or nonhealing of the ulcer, it should be corrected
by endovascular or open surgical means as appropriate.
The mere presence of PAD in a DFU patient, defined as
an ABI of <0.8, is associated with an increased risk of
limb loss.154 More profound degrees of ischemia increase
the risk of limb loss.152,155The incidence of PAD in people with diabetes appears
to have significantly increased during the last two de-
cades.156-159 In addition, the proportion of patients with
diabetes and wounds who have ischemic or neuroischemic
wounds has increased compared with neuropathic wounds
alone.156,157
The American Diabetes Association recommends that
all people with diabetes have ABI measurements performed
when they reach 50 years of age,17 and all people with dia-
betes and a foot wound should have pedal perfusion
assessed by ABI and either toe pressure or TcPO2.
160
ABI <0.8 increases amputation risk in the presence of a
foot wound in a patient with diabetes.154 Diminishing de-
grees of perfusion increase amputation risk, especially when
ABI is <0.4 and toe systolic pressure is <30 mmHg.161,162
“Subcritical” degrees of ischemia need to be considered
and may warrant intervention in a patient with diabetes
and a foot wound who does not respond to adequate off-
loading and débridement.
The systematic review163 commissioned by the SVS to
support these guidelines demonstrated that several tests are
available to predict wound healing in the setting of diabetic
foot; however, most of the available evidence evaluates only
TcPO2 and ABI. TcPO2 may be a more predictive test than
ABI, but both tests predicted healing and the risk of ampu-
tation. ABI measurements may be falsely elevated in a sig-
nificant number of patients with diabetes because of medial
calcinosis. Toe Doppler arterial waveforms and pressures
are helpful in such patients, and alternative perfusion mea-
surements may be especially applicable to patients with foot
wounds; a spectrum of ischemia may help quantify the de-
gree of ischemia, including pulse volume recordings, skin
perfusion pressures, and quantitative indocyanine green
angiography.
Recommendation 3. In patients with DFU who have
PAD, we recommend revascularization by either surgical
bypass or endovascular therapy (Grade 1B).
Recommendation 3 (technical and implementation
remarks).
d Prediction of patients most likely to require and
to benefit from revascularization can be based
on the SVS WIfI lower extremity threatened limb
classification.
d A combination of clinical judgment and careful inter-
pretation of objective assessments of perfusion
along with consideration of the wound and infection
extent is required to select patients appropriately for
revascularization.
d In functional patients with long-segment occlusive dis-
ease and a good autologous conduit, bypass is likely to
be preferable.
d In the setting of tissue loss and diabetes, prosthetic
bypass is inferior to bypass with vein conduit.
d The choice of intervention depends on the degree of
ischemia, the extent of arterial disease, the extent of
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the available expertise.
Evidence. The choice of endovascular therapy (EVT)
first vs surgical bypass for patients with tissue loss, PAD,
and diabetes is currently much debated.155 A recent
comprehensive evidence-based review could find no
clear evidence favoring EVT vs open bypass.151 There has
been a clear trend toward more widespread application of
EVT first,164 but no randomized trials have been performed
in patients with diabetes. Retrospective studies suggest
that EVT results in more repeated interventions and
perhaps lower healing rates, particularly in patients with
long-segment occlusive disease and more advanced tissue
ischemia (gangrene vs ulcer).165 At least in the United
States, the amputation rate for patients with DFUs has sta-
bilized or begun to decline166; increased rates of vascular
intervention (angiography, EVT, and open bypass) are
associated with this decline.167 A balanced view would
acknowledge that both EVT and open autologous vein
bypass are important means of revascularization as part
of a comprehensive approach to functional limb salvage
in patients with diabetes, lower extremity wounds, and
diabetes.168,169 It is presently unclear for which patients
EVT is preferable to open bypass. There are data suggesting
that the outcomes of EVT for TransAtlantic Inter-Society
Consensus type D femoropopliteal lesions are poor in
patients with diabetes. In functional patients with a good
autologous conduit, bypass is likely to be preferable in
this cohort.155 In the setting of tissue loss and diabetes,
prosthetic bypass is distinctly inferior to bypass with vein
conduit.170 For the wide spectrum of other patients with
diabetes or ulceration and gangrene with variable degrees of
arterial insufficiency, the choice of intervention likely
depends on the degree of ischemia, the extent of arterial
disease, the extent of the wound, the presence or absence of
infection, and the expertise of the practitioner.171
A final important point relates to the DFU complicated
by PAD with superimposed infection. The risk of amputa-
tion in a patient with a DFU correlates directly with
increasing infection severity. Infection is especially delete-
rious in patients with diabetes and PAD; in fact, PAD
plus infection tripled the likelihood of nonhealing in the
Eurodiale study.6,172 Aggressive control of infection with
appropriate antibiotics and timely, thorough débridement
as well as prompt revascularization once infection is
controlled are keys to managing this cohort of difficult pa-
tients.172 Therefore, after drainage of infection, revascular-
ization should be strongly considered if a diabetic foot
wound does not promptly respond to standard wound
care in accordance with the SVS WIfI system.6,172-174
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